Volume 78, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Currently available artemisinin-based combination therapies (ACTs) for malaria are inadequate. There remains an enormous unmet need for alternate artemisinin-based combination therapies. One of the fastest methods to identify promising artemisinin-based combination therapies is to look for synergistic or additive antimalarial interaction between artemisinin and an alternate drug against . Amphotericin B and clotrimazole are known drugs for treatment of human fungal infections. We repurposed clotrimazole or heat-treated amphotericin B in fixed ratio combination with artemisinin for antimalarial properties. Isobologram results show synergistic/additive interaction in both of the cases at therapeutically safe concentrations. Artemisinin, clotrimazole, and their synergistic combinations also decrease hemozoin production in parasitized erythrocytes. New permeation pathways induced in infected cells remain unaffected by drug combinations as indicated by sorbitol lysis. It would be interesting to extend the studies’ system.


Article metrics loading...

Loading full text...

Full text loading...



  1. Phillips RS, 2001. Current status of malaria and potential for control. Clin Microbiol Rev 14 : 208–226.
  2. WHO, 2006. World Health Organization. WHO guidelines for the treatment of malaria. Geneva, Switzerland.
  3. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJM, Talisuna AO, Pxoux S, Christophel EM, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nos-ten N, White NJ, 2006. Manslaughter by fake artesunate in Asia—will Africa be next? PLoS Med 3 : e197.
  4. New RRC, Chance ML, Heath S, 1981. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 8 : 371–381.
  5. Petit C, Cheron M, Joly V, Rodrigues JM, Bolard J, Gaboriau F, 1998. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. J Antimicrob Chemother 42 : 779–785.
  6. Gaboriau F, Chéron M, Petit C, Bolard J, 1997. Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother 41 : 2345–2351.
  7. Hatabu T, Takada T, Taguchi N, Suzuki M, Sato K, Kano S, 2005. Potent plasmodicidal activity of a heat-induced reformulation of deoxycholate-amphotericin B (fungizone) against Plasmodium falciparum. Antimicrob Agents Chemother 49 : 493–496.
  8. Tiffert TH, Ginsburg H, Krugliak M, Elford BC, Lew VL, 2002. Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. Proc Natl Acad Sci U S A 97 : 331–336.
  9. Trager W, Jensen JB, 1976. Human malaria parasites in continuous culture. Science 193 : 673–675.
  10. Lambros C, Vanderberg JP, 1979. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol 65 : 418–420.
  11. Fivelman QL, Adagu IS, Warhurt DC, 2004. Modified fixed ratio isobologram method for studying in vitro interactions between Atovaquone and Proguanil or dihydroartemisinin against drug resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48 : 4097–4102.
  12. Berenbaum MC, 1978. A method for testing synergy with any number of agents. J Infect Dis 137 : 122–130.
  13. Gupta S, Thapar MM, Wernsdorfer WH, Bjorkman A, 2002. In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob Agents Chemother 46 : 1510–1515.
  14. Sannella R, Messori L, Casini A, Vincieri FF, Bilia AR, Majori G, Severini C, 2007. Antimalarial properties of green tea. Biochem Biophys Res Commun 353 : 177–181.
  15. Elion GB, Singer S, Hitchings GH, 1954. Antagonists of nucleic acid derivatives VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 208 : 477–488.
  16. Akompong T, Ghori N, Haldar K, 2000. In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 44 : 88–96.
  17. Go ML, Liu M, Wilairat P, Rosenthal PJ, Saliba KJ, Kirk K, 2004. Antiplasmodial chalcones inhibit sorbitol-induced hemolysis of Plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 48 : 3241–3245.
  18. Desai SA, Krogstad DJ, McCleskey EW, 1993. A nutrient-permeable channel on the intraerythrocytic malaria parasite. Nature 362 : 643–646.
  19. Klayman DL, 1985. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228 : 1049–1055.
  20. Bhasin VK, Trager W, 1987. Gametocytocidal effect in vitro of cinchona alkaloids and derivatives on a Plasmodium falciparum clone. Acta Leiden 55 : 151–158.
  21. Bhasin VK, Nair L, 2003. ACT now—with caution—for malaria treatments. Lancet Infect Dis 3 : 609.
  22. Meshnick SR, 1994. The mode of action of antimalarial endo-peroxides. Trans R Soc Trop Med Hyg 88 : 31–32.
  23. WHO, 1998. World Health Organization. The use of artemisinin and its derivatives as antimalarial drugs. Report of a joint CTD/DMP/TDR informal consultation. Geneva, Switzerland.
  24. Ludwig UE, Webb RJ, van Goethem IDA, East JM, Lee AG, Kimura M, O’Neill PM, Bray PG, Ward SA, Krishna S, 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424 : 957–961.
  25. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P, 2000. Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet 39 : 255–270.
  26. Ashton M, Nguyen DS, Nguyen VH, Toufigh G, Trinh NH, Dinh XH, Nguyen TN, Le DC, 1998. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63 : 482–493.
  27. Bossche HV, Willemsens G, Cools W, Marichal P, Lauwers W, 1983. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans 11 : 665–667.
  28. Yoshida Y, Aoyama Y, 1987. Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevisiae microsomes. Biochem Pharmacol 36 : 229–235.
  29. Huy NT, Kamei K, Kondo Y, Serada S, Kanaori K, Takano R, Tajima K, Hara S, 2002. Effect of antifungal azoles on the heme detoxification systems of malaria parasite. J Biochem (Tokyo) 131 : 437–444.
  30. Klokouzas A, Barrand MA, Hladky SB, 2001. Effects of clotrimazole on transport mediated by multidrug resistance associated protein 1 (MRP1) in human erythrocytes and tumor cells. Eur J Biochem 268 : 6569–6577.
  31. Trivedi V, Chand P, Srivastava K, Puri SK, Maulik PR, Bandyo-padhyay U, 2005. Clotrimazole inhibits hemoperoxidase of Plasmodium falciparum and induces oxidative stress. J Biochem (Tokyo) 280 : 41129–41136.
  32. Benzaquen LR, Brugnara C, Byers HR, Gattoni-Celli S, Halperin JA, 1995. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat Med 1 : 534–540.
  33. Tiffert T, Staines HM, Ellory JC, Lew VL, 2002. Functional state of the plasma membrane Ca2+ pump in Plasmodium falciparum-infected human red blood cells. J Physiol 525 : 125–134.
  34. Aktas H, Fluckiger R, Acosta JA, Salvage JM, Palakurthi SS, Halperin JA, 1998. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci U S A 95: 8280–8285.
  35. Holt RJ, Newman RL, 1972. Laboratory assessment of the anti-mycotics drug clotrimazole. J Clin Pathol 25 : 1089–1097.
  36. Brugnara C, Armsby CC, Sakamoto M, Rifai N, Alper L, Platt OS, 1995. Oral administration of clotrimazole and blockade of human erythrocyte Ca2+ activated K+ channel: the imidazole ring is not required for inhibitory activity. J Pharmacol Exp Ther 273 : 266–272.
  37. Rifai N, Sakamoto M, Law T, Platt O, Mikati M, Armsby CC, Brugnara C, 1995. HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent. Clin Chem 41 : 387–391.
  38. Mishra LC, Bhattacharya A, Bhasin VK, 2007. Antiplasmodial interactions between artemisinin and triclosan or ketoconazole combinations against blood stages of Plasmodium falciparum in vitro. Am J Trop Med Hyg 73 : 497–501.
  39. Mahmoud AG, Rice LB, 1999. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12 : 501–517.
  40. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, Field-Ridley A, Avila N, Bacher J, Walsh TJ, 2001. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 45 : 857–869.
  41. Kharazmi A, Jepsen S, Andersen BJ, 1987. Generation of reactive oxygen radicals by human phagocytic cells activated by Plasmodium falciparum. Scand J Immunol 25 : 335–341.
  42. Bartlett K, Yau E, Hartsel SC, Hamer A, Tsai G, Bizzotto D, Wasan KM, 2004. Effect of heat-treated amphotericin B on renal and fungal cytotoxicity. Antimicrob Agents Chemother 48 : 333–336.
  43. Scheven M, Schwegler F, 1995. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 39 : 1779–1783.

Data & Media loading...

  • Received : 22 Oct 2007
  • Accepted : 28 Dec 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error